GSA Capital Partners LLP Purchases New Position in BioCryst Pharmaceuticals, Inc. $BCRX

GSA Capital Partners LLP purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, Holdings Channel reports. The fund purchased 90,210 shares of the biotechnology company’s stock, valued at approximately $902,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BCRX. Larson Financial Group LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,267 shares in the last quarter. Focus Partners Wealth acquired a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares in the last quarter. Hilltop Holdings Inc. bought a new stake in BioCryst Pharmaceuticals during the 1st quarter worth approximately $98,000. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $81,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BCRX. Cantor Fitzgerald lifted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 target price on the stock. Wedbush lowered their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Finally, Citizens Jmp lifted their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

BioCryst Pharmaceuticals Trading Down 2.4%

Shares of NASDAQ BCRX opened at $9.70 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.22. The firm’s 50-day moving average is $9.55 and its 200-day moving average is $8.88. The firm has a market capitalization of $2.48 billion, a PE ratio of -6.47 and a beta of 0.56.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. During the same period in the previous year, the firm posted $0.15 earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 33.6% compared to the same quarter last year. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.